First Trust Nasdaq Pharmaceuticals ETF
FTXH
8 hedge funds and large institutions have $2.9M invested in First Trust Nasdaq Pharmaceuticals ETF in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.76% less ownership
Funds ownership: 54.13% → 49.36% (-4.8%)
27% less funds holding
Funds holding: 11 → 8 (-3)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
42% less capital invested
Capital invested by funds: $5.04M → $2.9M (-$2.14M)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$704K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAWM
J. Arnold Wealth Management
Youngstown,
Ohio
|
-$1.64M |
| 2 |
Jane Street
New York
|
-$519K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$35K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$18.3K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$9K |
FTXH Hedge Fund Activity: Q1 2020 in Review
8 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q1 2020, worth a combined $2.9M — down 42% from $5.04M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FTXH and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $704K. The largest seller was J. Arnold Wealth Management, cutting an estimated $1.64M.
- 8 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q1 2020, down from 11 in Q4 2019.
- Funds reported $2.9M of First Trust Nasdaq Pharmaceuticals ETF stock for Q1 2020, down 42% quarter-over-quarter.
- 2 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q1 2020 and 3 closed out, a net change of -1 holder.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q1 2020 was Susquehanna International Group, an estimated $704K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q1 2020 was J. Arnold Wealth Management, an estimated $1.64M sold.
Based on aggregated 13F filings for Q1 2020.